FCGR2B

Across TCGA pan-cancer cohorts, FCGR2B mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of FCGR2B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FCGR2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FCGR2B is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where FCGR2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FCGR2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+1.077	<.001	12	view →
HNSC	Male	III,IV	−0.690	<.001	11	view →
COAD	Male	II,III,IV	−0.675	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

FCGR2B–CCRCC

Open the CCRCC breakdown →